Lima N. Viability testing and potential impacts on antimicrobial usage and antimicrobial resistance. 16B. ASRH Invited Speaker Session: Discovery and Translational Science: Antimicrobial resistance in the era of doxycycline post-exposure prophylaxis, HIV&AIDS+ASRH 2025, Adelaide. 18 September 2025.

Murray G. Mycoplasma genitalium and PEP: considerations, limitations, and mutations… 16B. ASRH Invited Speaker Session: Discovery and Translational Science: Antimicrobial resistance in the era of doxycycline post-exposure prophylaxis, HIV&AIDS+ASRH 2025, Adelaide. 18 September 2025.

Sweeney E. Potential impacts of doxycycline post-exposure prophylaxis on Neisseria gonorrhoeae AMR and novel molecular strategies for antimicrobial surveillance and resistance-guided management. 16B. ASRH Invited Speaker Session: Discovery and Translational Science: Antimicrobial resistance in the era of doxycycline post-exposure prophylaxis, HIV&AIDS+ASRH 2025, Adelaide. 18 September 2025.

Verich A. Mind the gaps: Systematic review and meta-analysis to assess publicly available Neisseria gonorrhoeae isolates with whole-genome sequences linked to antimicrobial resistance data. 15B. ASRH Session: Discovery and Translational Science: Abstracts, HIV&AIDS+ASRH 2025, Adelaide. 18 September 2025.

Herring E. Dead or alive: new precision tools for determining Mycoplasma genitalium and Neisseria gonorrhoeae viability. 15B. ASRH Session: Discovery and Translational Science: Abstracts, HIV&AIDS+ASRH 2025, Adelaide. 18 September 2025.

Vodstrcil L. Factors associated with treatment failure following male partner-treatment for bacterial vaginosis. 15A. ASRH Abstracts Session: Clinical management: Emerging STI treatment issues, HIV&AIDS+ASRH 2025, Adelaide. 18 September 2025.

Htaik K. Does pre-treatment with doxycycline improve the efficacy of combination minocycline and metronidazole for macrolide resistant mycoplasma genitalium infections? 15A. ASRH Abstracts Session: Clinical management: Emerging STI treatment issues, HIV&AIDS+ASRH 2025, Adelaide. 18 September 2025.

Ong J. Introduction: ASHRA Oration. 13E. 14. ASRH Plenary, HIV&AIDS+ASRH 2025, Adelaide. 18 September 2025.

Htaik K. A case-control study to investigate the aetiology of pelvic inflammatory disease. 13E. ASRH Abstract Session: Clinical management: STI clinical features, aetiology and improving testing and care access, HIV&AIDS+ASRH 2025, Adelaide. 17 September 2025.

Htaik K. Trends in infections detected in women with pelvic inflammatory disease over a decade. 13E. ASRH Abstract Session: Clinical management: STI clinical features, aetiology and improving testing and care access, HIV&AIDS+ASRH 2025, Adelaide. 17 September 2025.

Williams E. Controlled human infection model of oropharyngeal gonorrhoea. 12D. ASRH Discovery and Translational Science Session: The role of models in advancing understanding of Neisseria gonorrhoeae, HIV&AIDS+ASRH 2025, Adelaide. 17 September 2025.

Bryan E. A male genital Neisseria species model of infection (Virtual Presentation). 12D. ASRH Discovery and Translational Science Session: The role of models in advancing understanding of Neisseria gonorrhoeae, HIV&AIDS+ASRH 2025, Adelaide. 17 September 2025.

Guy R. Grant writing foundations. 8C. ECR Session: Essentials for Grant Success, HIV&AIDS+ASRH 2025, Adelaide. 16 September 2025.

Kong F. Planning for Impact. 8C. ECR Session: Essentials for Grant Success, HIV&AIDS+ASRH 2025, Adelaide. 16 September 2025.

Ong J. Grants & Impact 101. 8C. ECR Session: Essentials for Grant Success, HIV&AIDS+ASRH 2025, Adelaide. 16 September 2025.

Bradshaw C. BV partner treatment – practical use, how to roll out. 8E. Workshop: From Challenge to Opportunity: Practical SRH & HIV Hot Topics for General Practice, HIV&AIDS+ASRH 2025, Adelaide. 16 September 2025.

Treloar C. Changing the power relations of stigma for better quality of life. 7D. Insights to Action: Quality of Life in HIV Care Joint Symposium between NAPWHA and ViiV Healthcare, HIV&AIDS+ASRH 2025, Adelaide. 16 September 2025.

Pasricha S. Keynote Presentation: CRISPR technology and its use in diagnostics. 5. ASRH Opening Plenary, HIV&AIDS+ASRH 2025, Adelaide. 16 September 2025.

Treloar C. Acceptability of a community-controlled complaints portal for HIV stigma: Consultations with people living with HIV and community-based advocates. 2B. HIV&AIDS Abstract Session: Social, political & cultural aspects: Law, criminalisation, and digital platforms, HIV&AIDS+ASRH 2025, Adelaide. 15 September 2025.

Ong J. Preferences of men who have sex with men towards the distribution of HIV self-test kits through social networks: A discrete choice experiment. 2A. HIV&AIDS Abstract Session: Epidemiology, prevention & public health: Increasing testing and prevention, HIV&AIDS+ASRH 2025, Adelaide. 15 September 2025.

Vodstrcil L. Factors Associated With Treatment Failure Following Male Partner-Treatment for Bacterial Vaginosis. SY02.02, STI & HIV 2025 World Congress, Montreal. 30 July 2025.

Chow E. AI and Sexual Health. PL07.02, STI & HIV 2025 World Congress, Montreal. 30 July 2025.

Vodstrcil L. Supporting Couples and Clinicians to Implement Male Partner Treatment for BV. OA15.04, STI & HIV 2025 World Congress, Montreal. 30 July 2025.

Kong FYS. Screening Antimicrobial Fatty Acids for Treating Oral Gonorrhoea Using a Validated 2D Human Oral Cell Model. OA14.06, STI & HIV 2025 World Congress, Montreal. 30 July 2025.

Bradshaw C. StepUp Trial: Effects of Partner Treatment on Bacterial Vaginosis Treatment Outcome. SY11.02, STI & HIV 2025 World Congress, Montreal. 29 July 2025.

Huston W. Dead or Alive? Why It Matters for Diagnostics. SY10.04, STI & HIV 2025 World Congress, Montreal. 29 July 2025.

Applegate T. Advances in STI Point-of-Care Tests. SY10.03, STI & HIV 2025 World Congress, Montreal. 29 July 2025.

Applegate T. Is There a Pipeline of POC STI Tests That Would be Affordable in LMICs? SP05.05, STI & HIV 2025 World Congress, Montreal. 29 July 2025.

Ong J. Value of Multiple Diagnostic Tests to Achieve Triple Elimination of HIV, Syphilis and HBV. SY08.04, STI & HIV 2025 World Congress, Montreal. 29 July 2025.

Chow E. Applying Molecular-Viability Testing for Oropharyngeal Gonorrhoea: Results from the OMEGA3 Trial. AOS20.05, STI & HIV 2025 World Congress, Montreal. 29 July 2025.

Huston W. Molecular-viability Testing for Oropharyngeal Gonorrhoea: Updates. AOS20.04, STI & HIV 2025 World Congress, Montreal. 29 July 2025.

Kong FYS. How do we Optimise Sampling Techniques and Methods to Improve Drug Pharmacokinetics Data from the Mouth? AOS20.03, STI & HIV 2025 World Congress, Montreal. 29 July 2025.

Williams E. Are we Ready for a Human Challenge Model for Oropharyngeal Gonorrhoea? AOS20.02, STI & HIV 2025 World Congress, Montreal. 29 July 2025.

Applegate T. Back to the Future: Diagnostics 4.0 in an era of Digital/AI & Connectivity. AOS27, STI & HIV 2025 World Congress, Montreal. 28 July 2025.

Lima N. Performance of a novel molecular-phenotypic assay for viability and antibiotic susceptibility assessment of Neisseria gonorrhoeae (NG). OA04.04, STI & HIV 2025 World Congress, Montreal. 28 July 2025.

Huston W. Viability Assays: Which one Should you use? AOS15.02, STI & HIV 2025 World Congress, Montreal. 28 July 2025.

Ong J. Optimal Testing Frequency for Sexually Transmitted Infections Among Men Who Have Sex With Men and Transgender Women Who Use HIV Pre-Exposure Prophylaxis in Australia, Thailand and Brazil: A Cost-Effectiveness Analysis. PP06.79, STI & HIV 2025 World Congress, Montreal. 27 July 2025.

Kong FYS. Tetracycline-resistant Neisseria gonorrhoeae global estimates – impacts on doxyPEP implementation and monitoring. PP04.155, STI & HIV 2025 World Congress, Montreal. 27 July 2025.

Htaik K. Trends in Infections Detected in Women with Pelvic Inflammatory Disease over a Decade. PP04.152, STI & HIV 2025 World Congress, Montreal. 27 July 2025.

Wong A. Associations between frequency of chlamydia & gonorrhoeae screening and Ceftriaxone consumption in Australian gay & bisexual men (GBM) attending sexual health clinics (SHCs). PP04.140, STI & HIV 2025 World Congress, Montreal. 27 July 2025.

Ong J. HIV, Viral Hepatitis, and Syphilis Self-Testing Among Adolescents and Young Adults: A Systematic Review and Meta-Analysis. PP04.105, STI & HIV 2025 World Congress, Montreal. 27 July 2025.

Ong J. Preferences of Men Who Have Sex With Men Towards the Distribution of HIV Self-Test Kits Through Social Networks: A Discrete Choice Experiment. PP04.104, STI & HIV 2025 World Congress, Montreal. 27 July 2025.

Chow E. Understanding the Epidemiology, Clinical Characteristics and Infection Severity of Mpox Cases in 2024 Outbreaks in Victoria, Australia. PP04.35, STI & HIV 2025 World Congress, Montreal. 27 July 2025.

Wong A. What proportion of asymptomatic rectal Neisseria Gonorrhoeae (NG) infections are non-viable? A study combining culture and a novel molecular viability test. PP03.81, STI & HIV 2025 World Congress, Montreal. 27 July 2025.

Wong A. Closing the window between collection and culture: Does direct plating of swabs in the clinic improve yield of Neisseria Gonorrhoeae?. PP03.80, STI & HIV 2025 World Congress, Montreal. 27 July 2025.

Htaik K. Does Pre-Treatment With Doxycycline Improve the Efficacy of Combination Minocycline and Metronidazole for Macrolide Resistant Mycoplasma Genitalium Infections? PP03.46, STI & HIV 2025 World Congress, Montreal. 27 July 2025.

Htaik K. A case-control study to investigate the aetiology of pelvic inflammatory disease (PID). PP03.09, STI & HIV 2025 World Congress, Montreal. 27 July 2025.

Ong J. Overseas-Born Trans and Gender Diverse People’s Experiences With the Australian Sexual Health Services: A Qualitative Study. PP02.56, STI & HIV 2025 World Congress, Montreal. 27 July 2025.

Ong J. Preferences and Willingness to Use Pre-Exposure Prophylaxis for HIV Among Men Who Have Sex With Men in Mainland China and Hong Kong. PP02.55, STI & HIV 2025 World Congress, Montreal. 27 July 2025.

Chow E. Awareness, Usage, Beliefs and Concerns of Doxycycline Prophylaxis for STI Prevention Among Gay and Bisexual Men, Transgender and Non-Binary People in Australia. PP02.18, STI & HIV 2025 World Congress, Montreal. 27 July 2025.

Ong J. Generalizable Segment Anything Model Via Selection Strategy for Skin Lesion Segmentation in Sexual Transmitted Infection Cases. PP01.55, STI & HIV 2025 World Congress, Montreal. 27 July 2025.

Huaman Torres JLA. Sequencing Cultured Isolates of Mycoplasma Genitalium Using Oxford Nanopore. PP01.42, STI & HIV 2025 World Congress, Montreal. 27 July 2025.

Applegate T. Advancing Diagnostics for Neisseria Gonorrhoeae Through Explainable Machine Learning. PP01.24, STI & HIV 2025 World Congress, Montreal. 27 July 2025.

Nugent H. Comparative Transcriptomic Profiling of Mycoplasma genitalium Reveals Growth Phase Dynamics and Strain Specific Responses to Antibioticsveals Growth Phase Dynamics and Strain Specific Responses to Antibiotics. PP01.16, STI & HIV 2025 World Congress, Montreal. 27 July 2025.

Lima N. Viability assessment of Neisseria gonorrhoeae in male urine samples by a novel nucleic acid amplification test (NAAT). ESCMID Global 2025 , Vienna. 14 April 2025.

Kong FYS. From testing to treatment of STIs: new research from Australia – Maintaining treatments in the pipeline for oral gonorrhoea. British Columbia Centers for Disease Control Grand Rounds, Vancouver. 20 November 2024.

Hamza SA, Paolini R, Moore C, McCullough M, Unemo M, Hocking JS, Celentano A, Kong FYS. Development of an in-vitro 2D human oral cell model to explore antimicrobial resistance in Neisseria gonorrhoeae. BacPath 2024, New South Wales, Australia. 13 November 2024.

Bradshaw CS. Latest science, resistance, and recommendations for treatment of Mycoplasma genitalium. American Society for Microbiology, Washington DC, USA. 6/2022.

Bradshaw CS. Mycoplasma genitalium: evidence to inform testing and treatment University of Washington, Seattle USA, Research Seminar Series, 5/2022

Bradshaw CS: Molecular-guided therapy for Mycoplasma genitalium, European Society of Clinical Microbiology and Infectious Diseases, 4/2022

Bradshaw CS Implementation of STI point of care testing. AChSHM Annual Scientific Meeting, 19 March 2022.

Bradshaw CS. Plenary: M. genitalium Clinical Care – Resistance-Guided Treatment 21st World Congress of the International Union against STIs, 12/2021

Bradshaw CS: Mycoplasma genitalium: Approaches to testing and treatment. 26th Annual Scientific Session of the Sri Lanka College of Sexual Health and HIV medicine, 12/2021

Bradshaw CS: Clinical problems, scientific solutions. Mycoplasma genitalium – our emerging STI superbug. MIDS & The Centre to Impact AMR. Inaugural joint GRAND ROUNDS Event. Alfred Hospital, 10/2021

Bradshaw CS: Mycoplasma genitalium: Where to next? Australasian Sexual Health Conference, 9/021

Bradshaw CS: Mycoplasma genitalium: Australasian Society for HIV Medicine and Australasian Chapter of Sexual Health Update. 7/2021

Bradshaw CS: New treatment approaches for M.genitalium: STI and HIV World Congress 7/2021

Bradshaw CS: Resistance-guided therapy for M.genitalium: STI and HIV World Congress 7/2021

Bradshaw CS. M.genitalium: When to test and when to treat, Invited Webinar Series of International Union for STIs 6/2021

Bradshaw CS. Complexity, Challenges, Change in Sexual Health. MG update on resistant guided care, AChSHM ASM 2021 3/2021

Bradshaw CS. Mycoplasma genitalium Update. Royal Australian College of General Practitioners 3/2021